Navigation Links
Could fungal collection hold the key to new life-saving drugs?

Scientists may be one step closer to finding new drugs to fight MRSA, cancers and other diseases, after CABI, a leading bioservices organisation announced that its fungal collection will be screened by the University of Strathclyde.

CABI houses one of the world’s largest genetic resource collections of fungi, numbered at over 28,000 strains, including Fleming’s original penicillin producing isolate. They will be supplying the University of Strathclyde’s Institute for Drug Research (SIDR) with extracts from filamentous fungi which will be screened to identify pharmaceutically active compounds, which could potentially be developed into drugs.

Joan Kelley, Executive Director Bioservices, CABI said:

“This is a really exciting collaboration and we are looking forward to working with the expertise of the scientists at SIDR. We are hopeful that our partnership will prove the winning formula for discovering new pharmaceutical drugs to fight cancers, diseases and resistant strains of infections such as MRSA.”

SIDR brings together scientists from different disciplines to focus on drug discovery. They have developed test systems to detect biological activity in samples of natural products that could lead to new medicinal products. Previous work at SIDR found activities from plant extracts against diabetes, obesity and psoriasis.

Professor Alan Harvey, Director of SIDR said:

“We are delighted to be working with CABI and to have access to their fantastic source of fungal samples. We hope that this novel source of chemical diversity will contain new compounds that can be used to point the way to new drugs for serious diseases.”

CABI currently uses its fungal collection, along with the expertise of its scientists to offer a range of services to businesses, including fungal identification, sales, preservations, patenting, training and consultancy. The partnership with SIDR will see CABI’s collection taken one step further, with the fungi being exploited for natural products.

Although using biotechnology to develop new drugs is by no means simple, the industry has seen steady success over the past few years. Between 2000 and 2005, over 20 new drugs were released onto the market originating from natural sources. And although this is the first time SIDR has worked with fungal cultures, there are a number of prescription drugs deriving from metabolites produced by fungi that have been on the market for many years. These include immunosuppressive agents, antibiotics such as penicillin, lipid lowering agents and anti-fungal drugs.


'"/>

Source:CABI


Related biology news :

1. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
2. Spider Venom Could Yield Eco-Friendly Insecticides
3. New Breast Cancer Test Could Save Lives
4. Discovery Could Lead To Novel Approaches In HIV Treatment
5. New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal
6. Protein Discovery Could Unlock The Secret To Better TB Treatment
7. Could microbes solve Russias chemical weapons conundrum?
8. Natural Killers Could Lead to New Hepatitis Treatments
9. Could better mangrove habitats have spared lives in the 2004 tsunami?
10. Cant serve an ace? Could be muscle fatigue
11. Transplanting Animal Organs Could Soon Be A Reality

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced ... U.K. Biobank and GSK to generate genetic sequence data from ... initiative will enable researchers to gain valuable insights to support ... range of serious and life threatening diseases. ... Genetic evidence has ...
(Date:3/22/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... ), a clinical-stage pharmaceutical company focused on the ... that Dr. Miriam Kidron , Oramed,s Chief ... Insulin for Diabetes Treatment: Bypassing the Roadblock," at ... Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
(Date:3/22/2017)... Maryland (PRWEB) , ... March 21, 2017 , ... ... Life Science Chief Executive Officer Forum on March 23-24 in San Diego. The ... medical device and diagnostic industries. , Benchworks Vice President Christian Meyer will also ...
Breaking Biology Technology: